Facilitation of fas mediated apoptosis of human chondrocytes by the proteasome inhibitor and actinomycin D

J Rheumatol. 2003 Mar;30(3):550-8.

Abstract

Objective: We investigated the susceptibility of chondrocytes to apoptosis induced by anti-Fas and various potentiators, and the relevant signaling pathway.

Methods: Chondrocytes were cultured from cartilages obtained at the time of joint replacement surgery for knee osteoarthritis (OA) or femur neck fracture. Fas receptor ligation was performed with agonistic anti-Fas antibody (clone CH-11) at concentrations ranging from 0.5 to 1.0 micro g/ml. Mitogen activated protein kinase inhibitors SB203580 and PD98059, cycloheximide, bisindolylmaleimide, actinomycin D, or MG132 were added with anti-Fas to facilitate cell death. Chondrocyte surface expression of Fas was analyzed by FACS, and the expression of apoptosis related proteins analyzed by Western blot.

Results: Cell death increased upon coculture with 0.5 micro g/ml of anti-Fas and 0.2 micro g/ml of actinomycin D or 20 micro M MG132. Apoptosis potentiated by actinomycin D or MG132 was effectively inhibited by caspase inhibitors, implicating the involvement of the caspase cascade in chondrocyte apoptosis. Compared with untreated cells or actinomycin D treated cells, cells treated with MG132 showed distinct shifts in the distribution of surface Fas fluorescence. Although concentrations of Bcl-2, Bax, FLICE inhibitory protein (FLIP), and Fas ligand were unaffected by MG132 or actinomycin D, both treatments led to a significant increase of p53. The expression of the p53 response proteins, MDM2 and p21, was elevated in MG132 treated chondrocytes.

Conclusion: Our results suggest that chondrocytes can be rendered sensitive to anti-Fas mediated apoptosis by the proteasome inhibitor MG132 and the transcription inhibitor actinomycin D. MG132 and actinomycin D show different characteristics in terms of apoptosis signaling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Apoptosis / drug effects*
  • Apoptosis / physiology
  • Cartilage, Articular / cytology
  • Caspase Inhibitors
  • Cells, Cultured
  • Chondrocytes / cytology*
  • Chondrocytes / drug effects
  • Cycloheximide / pharmacology
  • Cysteine Endopeptidases
  • Cysteine Proteinase Inhibitors / pharmacology
  • Dactinomycin / pharmacology*
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Imidazoles / pharmacology
  • Indoles / pharmacology
  • Leupeptins / pharmacology
  • MAP Kinase Signaling System / drug effects
  • Maleimides / pharmacology
  • Multienzyme Complexes / antagonists & inhibitors*
  • Proteasome Endopeptidase Complex
  • Protein Synthesis Inhibitors / pharmacology*
  • Pyridines / pharmacology
  • fas Receptor / immunology
  • fas Receptor / metabolism*

Substances

  • Antibodies, Monoclonal
  • Caspase Inhibitors
  • Cysteine Proteinase Inhibitors
  • Enzyme Inhibitors
  • Imidazoles
  • Indoles
  • Leupeptins
  • Maleimides
  • Multienzyme Complexes
  • Protein Synthesis Inhibitors
  • Pyridines
  • fas Receptor
  • Dactinomycin
  • Cycloheximide
  • Cysteine Endopeptidases
  • Proteasome Endopeptidase Complex
  • bisindolylmaleimide
  • SB 203580
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde